Pfizer (PFE) Minority Interest (2009 - 2026)

Pfizer (PFE) has 18 years of Minority Interest data on file, last reported at $303.0 million in Q1 2026.

• Quarterly Minority Interest rose 1.34% year-over-year to $303.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $303.0 million (up 1.34% YoY) and the FY2025 annual result came in at $299.0 million, up 1.7% from the prior year.
• Minority Interest improved to $303.0 million in Q1 2026 per PFE's latest filing, from $299.0 million in the prior quarter.
• Across five years, Minority Interest topped out at $317.0 million in Q2 2025 and bottomed at $227.0 million in Q4 2022.
• The 5-year median for Minority Interest is $274.0 million (2023), against an average of $277.6 million.
• The widest annual swing landed in 2022, when Minority Interest fell 18.64%; it then advanced 18.94% in 2023.
• Tracing PFE's Minority Interest over 5 years: stood at $256.0 million in 2022, then climbed by 7.03% to $274.0 million in 2023, then increased by 7.3% to $294.0 million in 2024, then rose by 1.7% to $299.0 million in 2025, then grew by 1.34% to $303.0 million in 2026.
• Per Business Quant, the three latest PFE Minority Interest figures stand at $303.0 million (Q1 2026), $299.0 million (Q4 2025), and $295.0 million (Q3 2025).

Peer Comparison